EOLS

Evolus Inc

9.30

Sep 04 • 3:59 PM ET +0.25 (2.76%)

9.19

Aftermarket • 6:36 PM ET -0.11 (-1.18%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: INMD ALGN BLCO GMED ABT BSX EW MDT AXSM GKOS

| Held by: IWM VTI IWO VXF XPH SCHA IHE VTWO IWC GSSC

Scroll to Statements

Index	RUT
Market Cap	614.27M
Enterprise Value	733.90M
Income	-34.33M
Sales	316.49M
Book/sh	-0.47
Cash/sh	0.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	334
IPO	Feb 08, 2018

P/E	-
Forward P/E	37.41
PEG	-
P/S	1.94
P/B	-
P/C	13.60
P/FCF	-
EV/EBITDA	-
EV/Sales	2.32
Quick Ratio	1.28
Current Ratio	1.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.53
EPS next Y	0.25
EPS next Q	-0.07
EPS this Y	90.44%
EPS next Y	691.84%
EPS next 5Y	-
EPS past 3/5Y	15.49% 30.19%
Sales past 3/5Y	25.98% 39.36%
EPS Y/Y TTM	45.83%
Sales Y/Y TTM	13.87%
EPS Q/Q	54.03%
Sales Q/Q	21.18%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	122.22% 3.11%

Insider Own	12.36%
Insider Trans	-3.19%
Inst Own	73.43%
Inst Trans	6.32%
ROA	-14.40%
ROE	-18729.61%
ROIC	-26.14%
Gross Margin	64.95%
Oper. Margin	-6.51%
Profit Margin	-10.85%
SMA20	8.54%
SMA50	27.98%
SMA200	53.58%
Trades

Shs Outstand	66.01M
Shs Float	57.89M
Short Float	10.11%
Short Ratio	6.51
Short Interest	5.85M
52W High	9.15 1.64%
52W Low	3.86 140.93%
Volatility	2.97% 4.82%
ATR (14)	0.36
RSI (14)	73.17
Beta	1.33
Rel Volume	0.77
Avg Volume	899.62K
Volume	696,364

Perf Week	4.73%
Perf Month	25.51%
Perf Quarter	39.43%
Perf Half Y	68.17%
Perf YTD	39.85%
Perf Year	23.83%
Perf 3Y	-6.16%
Perf 5Y	-3.33%
Perf 10Y	-
Recom	1.29
Target Price	15.00
Prev Close	9.05
Price	9.30
Change %	2.76%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Downgrade	Needham	Buy → Hold
Apr-17-25	Initiated	BTIG Research	Buy	$21
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

Sep-01-26 11:37AM	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture (PR Newswire)
Aug-06-26 01:07AM	Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... (GuruFocus.com) +19.90%
Aug-05-26 04:05PM	Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook (Business Wire)
Aug-04-26 08:30AM	Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand (Business Wire)
Jul-22-26 08:30AM	Evolus to Report Second Quarter Financial Results on August 5, 2026 (Business Wire)
04:05PM	Loading…
Jul-10-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-08-26 09:00AM	Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality (Business Wire)
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire) -5.58%
May-19-26 08:30AM	Evolus to Participate in The Jefferies Global Healthcare Conference (Business Wire)
May-11-26 08:30AM	Evolus Announces Commercial Launch of Estyme Injectable Hyaluronic Acid Gels in Europe (Business Wire)
May-04-26 08:23PM	Evolus, Inc. Q1 2026 Earnings Call Summary (Moby) +14.16%
04:05PM	Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook (Business Wire)
Apr-14-26 08:30AM	Evolus to Report First Quarter Financial Results on May 4, 2026 (Business Wire)
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
08:00AM	Loading…
Mar-31-26 08:00AM	Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference (Business Wire)
Mar-20-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-04-26 08:30AM	Evolus, Inc. Q4 2025 Earnings Call Summary (Moby) +35.35%
12:01AM	Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
Mar-03-26 07:02PM	Evolus Q4 Earnings Call Highlights (MarketBeat)
06:05PM	Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates (Zacks)
04:05PM	Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 (Business Wire)
Feb-25-26 07:25PM	Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:00AM	Evolus to Participate in The Leerink Partners Global Healthcare Conference (Business Wire)
Feb-24-26 10:00AM	Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-17-26 08:00AM	Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 (Business Wire)
Feb-13-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-09-26 02:13PM	Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating (Insider Monkey) -5.78%
Feb-04-26 07:40AM	Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Jan-09-26 08:30AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue (Business Wire)
11:10PM	Loading…
Dec-15-25 11:10PM	Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics (Insider Monkey)
Nov-14-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-25 12:04AM	Evolus Inc (EOLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +5.43%
Nov-05-25 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.24%
04:05PM	Evolus Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-30-25 10:00AM	Earnings Preview: Prestige Consumer Healthcare (PBH) Q2 Earnings Expected to Decline (Zacks)
Oct-29-25 10:00AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-28-25 08:00AM	Evolus to Participate in 2025 Stifel Healthcare Conference (Business Wire)
Oct-22-25 08:00AM	Evolus to Report Third Quarter Financial Results on November 5, 2025 (Business Wire)
Oct-10-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-25 09:03AM	Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse Filler Launch (PR Newswire)
Sep-12-25 05:30PM	Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.79%
Sep-08-25 08:30AM	Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer (Business Wire)
Aug-25-25 08:00AM	Evolus Announces Positive Data From Pivotal Trial for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp (Business Wire)
Aug-20-25 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product (Business Wire)
Aug-08-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-05-25 06:30PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -28.51%
04:05PM	Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Jul-31-25 10:00AM	Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:05AM	Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau as a Top Performer Among Leading Neurotoxins (Business Wire)
Jul-29-25 10:00AM	Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 08:05AM	Evolus to Report Second Quarter Financial Results on August 5, 2025 (Business Wire)
Jul-11-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-25 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in France (Business Wire)
Jun-13-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-10-25 08:00AM	Evolysse Recognized in 2025 Shape Skin Awards (Business Wire)
May-27-25 04:15PM	Evolus Announces Departure of its Chief Financial Officer (Business Wire) -5.20%
May-22-25 08:00AM	Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire)
May-16-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-25 09:51AM	Evolus, Inc. (EOLS): A Bull Case Theory (Insider Monkey)
May-08-25 09:47AM	Q1 2025 Evolus Inc Earnings Call (Thomson Reuters StreetEvents) -14.20%
03:28AM	Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
May-07-25 07:14PM	Evolus projects $345M-$355M revenue for 2025 with new product launches (Seeking Alpha)
07:13PM	Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:55PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports First Quarter 2025 Results (Business Wire)
May-05-25 04:05PM	Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility (Business Wire)
May-01-25 07:30AM	SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-23-25 08:00AM	Evolus to Report First Quarter Financial Results on May 7, 2025 (Business Wire) +7.36%
Apr-22-25 07:10PM	Evolus: Two-Product Aesthetics Company With A Competitive Edge (Seeking Alpha)
Apr-18-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:00AM	Evolus Announces Commercial Launch of Evolysse (Business Wire)
Apr-15-25 08:00AM	Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse Injectable Hyaluronic Acid Gels (Business Wire)
Mar-25-25 08:00AM	Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-21-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-10-25 04:53PM	Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas (Motley Fool) -6.63%
Mar-05-25 07:13AM	Q4 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
Mar-04-25 05:25PM	Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance (Business Wire)
Mar-02-25 06:08PM	Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 08:00AM	Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences (Business Wire)
Feb-20-25 08:00AM	Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit (Business Wire)
Feb-18-25 08:00AM	Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 (Business Wire)
Feb-14-25 08:53AM	Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Feb-13-25 01:30PM	Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire) +5.47%
Feb-07-25 07:09PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-22-25 07:46AM	Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? (Zacks)
Jan-21-25 04:04PM	Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere Here's Why (Investor's Business Daily) +28.26%
08:00AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Companys Guidance (Business Wire)
Jan-17-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 09:55AM	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-14-24 09:35AM	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) (Zacks)
Nov-07-24 06:00AM	Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges (GuruFocus.com) -14.99%
Nov-06-24 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 08:00AM	Evolus to Participate in Stifel 2024 Healthcare Conference (Business Wire)
Oct-31-24 02:02PM	Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation (Business Wire)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

PresidentMr. David Moatazedi

Chief Financial OfficerMs. Tatjana Mitchell

Dip.SportMedDr. Rui Avelar C.CFP

Head of Global Investor Relations & Corporate CommunicationsMr. Nareg Sagherian

Senior Vice President of SalesMr. Kurt Knab

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOATAZEDI DAVID	See Remarks	Sep 02 '26	Sale	9.04	105,108	950,019	499,592	Sep 04 07:04 PM
DAVID MOATAZEDI	Officer	Sep 02 '26	Proposed Sale	9.04	105,108	950,019		Sep 02 04:55 PM
Avelar Rui	See Remarks	Mar 20 '26	Sale	4.75	3,119	14,815	427,423	Mar 20 07:19 PM
MOATAZEDI DAVID	See Remarks	Mar 20 '26	Sale	4.75	13,669	64,929	604,700	Mar 20 07:19 PM
MOATAZEDI DAVID	See Remarks	Mar 16 '26	Option Exercise	0.00	67,489	0	735,089	Mar 18 08:00 PM
MOATAZEDI DAVID	See Remarks	Mar 17 '26	Sale	4.89	116,720	570,562	618,369	Mar 18 08:00 PM
Avelar Rui	See Remarks	Mar 16 '26	Option Exercise	0.00	8,804	0	460,538	Mar 18 08:00 PM
Avelar Rui	See Remarks	Mar 17 '26	Sale	4.89	29,996	146,629	430,542	Mar 18 08:00 PM
MOATAZEDI DAVID	See Remarks	Dec 22 '25	Sale	7.15	10,539	75,361	354,388	Dec 29 06:42 PM
Avelar Rui	See Remarks	Dec 22 '25	Sale	7.15	2,261	16,168	356,821	Dec 29 06:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EOLS

Evolus Inc

Upgrade your Finviz experience